基本信息
浏览量:1
职业迁徙
个人简介
Research interests
Professor Iredell conducts basic and clinical research, combining his clinical expertise in critical care and long-standing research in molecular genetics. He develops and coordinates nationwide clinical trials related to life-threatening infections. His research covers critical infections and microbial ecology, especially in relation to transmissible antimicrobial resistance in bacteria.
Recent and contemporary projects include the study of bacterial load in septic shock (the BLISS study) and on transmissible resistance genetics in organisms such as E coli and Klebsiella sp, commonly implicated in life-threatening septic shock. Studies on the geographic distribution (Australia and global) and temporal variation of the antibiotic resistance gene pool are also underway (with Australian data implicating limited diversity in the transmissible antibiotic resistance gene pool). The team will exploit these data to develop diagnostic tests (using human blood) for key antibiotic resistance markers in Enterobacteriaceae, at the point of presentation to hospital with severe sepsis. His team seeks to better understand the associations between resistance genes conferring key phenotypes and their predominant means of spread, to help inform future surveillance and targeting of diagnostics.
Since antibiotic therapy is the cornerstone of managing critical infections, understanding the effects of antibiotics on the human microflora and on subsequent development of antibiotic resistance is crucial. Professor Iredell’s team is studying the impact of antibiotics on the microbial ecology of humans, and the correlations between antibiotics that cause greater disturbance of major bacteria in the microbiota and subsequent colonisation by antibiotic-resistant bacteria. New studies are investigating whether selective digestive tract decontamination with different types of antibiotics is associated with differing levels of disturbance of gut microflora and of antibiotic resistance, and the impact of such strategies on ICU outcomes.
Additional work includes specific manipulation of plasmid systems to reverse engineer antibiotic susceptibility in bacteria in vivo, and the targeting of specific bacterial clones with bacteriophage therapy and building a (globally-relevant) bank of probiotic plasmids that can protect the gut microflora.
Professor Iredell conducts basic and clinical research, combining his clinical expertise in critical care and long-standing research in molecular genetics. He develops and coordinates nationwide clinical trials related to life-threatening infections. His research covers critical infections and microbial ecology, especially in relation to transmissible antimicrobial resistance in bacteria.
Recent and contemporary projects include the study of bacterial load in septic shock (the BLISS study) and on transmissible resistance genetics in organisms such as E coli and Klebsiella sp, commonly implicated in life-threatening septic shock. Studies on the geographic distribution (Australia and global) and temporal variation of the antibiotic resistance gene pool are also underway (with Australian data implicating limited diversity in the transmissible antibiotic resistance gene pool). The team will exploit these data to develop diagnostic tests (using human blood) for key antibiotic resistance markers in Enterobacteriaceae, at the point of presentation to hospital with severe sepsis. His team seeks to better understand the associations between resistance genes conferring key phenotypes and their predominant means of spread, to help inform future surveillance and targeting of diagnostics.
Since antibiotic therapy is the cornerstone of managing critical infections, understanding the effects of antibiotics on the human microflora and on subsequent development of antibiotic resistance is crucial. Professor Iredell’s team is studying the impact of antibiotics on the microbial ecology of humans, and the correlations between antibiotics that cause greater disturbance of major bacteria in the microbiota and subsequent colonisation by antibiotic-resistant bacteria. New studies are investigating whether selective digestive tract decontamination with different types of antibiotics is associated with differing levels of disturbance of gut microflora and of antibiotic resistance, and the impact of such strategies on ICU outcomes.
Additional work includes specific manipulation of plasmid systems to reverse engineer antibiotic susceptibility in bacteria in vivo, and the targeting of specific bacterial clones with bacteriophage therapy and building a (globally-relevant) bank of probiotic plasmids that can protect the gut microflora.
研究兴趣
论文共 150 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Communicable diseases intelligence (2018) (2023)
Martin Plymoth, Stephanie A. Lynch,Ameneh Khatami, Holly A. Sinclair,Jessica C. Sacher,Jan Zheng,Ruby CY. Lin,Jonathan R. Iredell
medRxiv (Cold Spring Harbor Laboratory) (2023)
引用0浏览0引用
0
0
Journal of Medical Radiation Sciencesno. 1 (2023): 40-45
引用0浏览0引用
0
0
Jason P. Gordon,Amer Al Taie,Ryan L. Miller,James W. Dennis,Mark A. T. Blaskovich,Jonathan R. Iredell,John D. Turnidge,Geoffrey W. Coombs, David Charles Grolman, Jacqueline Youssef
Infectious diseases and therapyno. 7 (2023): 1875-1889
Rebekah M Dedrick,Bailey E Smith,Madison Cristinziano,Krista G Freeman,Deborah Jacobs-Sera,Yvonne Belessis,A Whitney Brown,Keira A Cohen,Rebecca M Davidson,David van Duin, Andrew Gainey, Cristina Berastegui Garcia,
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn